225 related articles for article (PubMed ID: 16616962)
1. Discovery of TSAO derivatives with an unusual HIV-1 activity/resistance profile.
de Castro S; García-Aparicio C; Van Laethem K; Gago F; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Antiviral Res; 2006 Aug; 71(1):15-23. PubMed ID: 16616962
[TBL] [Abstract][Full Text] [Related]
2. 4"-H-TSAO-T, a novel prototype in the HIV-1 specific TSAO family.
Lobatón E; Velázquez S; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):711-4. PubMed ID: 11563098
[TBL] [Abstract][Full Text] [Related]
3. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase.
Velázquez S; Chamorro C; Pérez-Pérez MJ; Alvarez R; Jimeno ML; Martín-Domenech A; Pérez C; Gago F; De Clercq E; Balzarini J; San-Félix A; Camarasa MJ
J Med Chem; 1998 Nov; 41(23):4636-47. PubMed ID: 9804703
[TBL] [Abstract][Full Text] [Related]
4. Novel [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2" -dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity.
de Castro S; Lobatón E; Pérez-Pérez MJ; San-Félix A; Cordeiro A; Andrei G; Snoeck R; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
J Med Chem; 2005 Feb; 48(4):1158-68. PubMed ID: 15715482
[TBL] [Abstract][Full Text] [Related]
5. "Second generation" of TSAO compounds directed against HIV-1 TSAO-resistant strains.
Lobatón E; Velázquez S; Pérez-Pérez MJ; Jimeno ML; San-Félix A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):707-10. PubMed ID: 11563097
[TBL] [Abstract][Full Text] [Related]
6. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position.
Bonache MC; Chamorro C; Velázquez S; De Clercq E; Balzarini J; Barrios FR; Gago F; Camarasa MJ; San-Félix A
J Med Chem; 2005 Oct; 48(21):6653-60. PubMed ID: 16220981
[TBL] [Abstract][Full Text] [Related]
7. Novel concepts in the treatment of human immunodeficiency virus type 1 (HIV-1) infections by HIV-1-specific reverse transcriptase inhibitors.
Balzarini J
Verh K Acad Geneeskd Belg; 1995; 57(6):575-600. PubMed ID: 8686372
[TBL] [Abstract][Full Text] [Related]
8. An approach towards the synthesis of potential metal-chelating TSAO-T derivatives as bidentate inhibitors of human immunodeficiency virus type 1 reverse transcriptase.
Chamorro C; Camarasa MJ; Pérez-Pérez MJ; de Clercq E; Balzarini J; San Félix A
Antivir Chem Chemother; 1998 Sep; 9(5):413-22. PubMed ID: 9875394
[TBL] [Abstract][Full Text] [Related]
9. Site-directed mutagenesis of human immunodeficiency virus type 1 reverse transcriptase at amino acid position 138.
Pelemans H; Aertsen A; Van Laethem K; Vandamme AM; De Clercq E; Pérez-Pérez MJ; San-Félix A; Velázquez S; Camarasa MJ; Balzarini J
Virology; 2001 Feb; 280(1):97-106. PubMed ID: 11162823
[TBL] [Abstract][Full Text] [Related]
10. Hybrids of [TSAO-T]-[foscarnet]: The first conjugate of foscarnet with a non-nucleoside reverse transcriptase inhibitor through a labile covalent ester bond.
Velázquez S; Lobatón E; De Clercq E; Koontz DL; Mellors JW; Balzarini J; Camarasa MJ
J Med Chem; 2004 Jun; 47(13):3418-26. PubMed ID: 15189038
[TBL] [Abstract][Full Text] [Related]
11. Structure-activity relationships of [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]- 3'-spiro-5' '-(4' '-amino-1' ',2' '-oxathiole-2' ',2' '-dioxide)thymine derivatives as inhibitors of HIV-1 reverse transcriptase dimerization.
Sluis-Cremer N; Hamamouch N; San Félix A; Velazquez S; Balzarini J; Camarasa MJ
J Med Chem; 2006 Aug; 49(16):4834-41. PubMed ID: 16884295
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and in vitro activity of novel N-3 acylated TSAO-T compounds against HIV-1 and HCV.
Moura M; Josse S; Nguyen Van Nhien A; Fournier C; Duverlie G; Castelain S; Soriano E; Marco-Contelles J; Balzarini J; Postel D
Eur J Med Chem; 2011 Oct; 46(10):5046-56. PubMed ID: 21880398
[TBL] [Abstract][Full Text] [Related]
13. Monitor-chemistry: antiretrovirals: the first [Foscarnet]-[TSAO-T] conjugates.
Félix AS
Drug Discov Today; 2005 Mar; 10(6):446. PubMed ID: 15808824
[No Abstract] [Full Text] [Related]
14. Presence of 2',5'-Bis-O-(tert-butyldimethylsilyl)-3'-spiro-5"-(4"-amino-1",2"-oxath iole-2",2"-dioxide) (TSAO)-resistant virus strains in TSAO-inexperienced HIV patients.
Van Laethem K; Schmit JC; Pelemans H; Balzarini J; Witvrouw M; Pérez-Pérez MJ; Camarasa MJ; Esnouf RM; Aquaro S; Cenci A; Perno CF; Hermans P; Sprecher S; Ruiz L; Clotet B; Van Wijngaerden E; Van Ranst M; Desmyter J; De Clercq E; Vandamme AM
AIDS Res Hum Retroviruses; 2000 Jun; 16(9):825-33. PubMed ID: 10875608
[TBL] [Abstract][Full Text] [Related]
15. Identification of a putative binding site for [2',5'-bis-O-(tert-butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5''-(4''-amino-1'',2''-oxathiole-2'',2''-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase.
Rodríguez-Barrios F; Pérez C; Lobatón E; Velázquez S; Chamorro C; San-Félix A; Pérez-Pérez MJ; Camarasa MJ; Pelemans H; Balzarini J; Gago F
J Med Chem; 2001 Jun; 44(12):1853-65. PubMed ID: 11384232
[TBL] [Abstract][Full Text] [Related]
16. Regiospecific synthesis and anti-human immunodeficiency virus activity of novel 5-substituted N-alkylcarbamoyl and N,N-dialkylcarbamoyl 1,2,3-triazole-TSAO analogues.
Velázquez S; Alvarez R; Pérez C; Gago F; De Clercq E; Balzarini J; Camarasa MJ
Antivir Chem Chemother; 1998 Nov; 9(6):481-9. PubMed ID: 9865386
[TBL] [Abstract][Full Text] [Related]
17. Unusual lability of 5'-O-tert-butyldimethylsilyl group on 4''-acyl TSAO derivatives.
de Castro S; Pérez-Pérez MJ; Lobatón E; De Clercq E; Balzarini J; Camarasa MJ; Velázquez S
Nucleosides Nucleotides Nucleic Acids; 2003; 22(5-8):959-61. PubMed ID: 14565321
[No Abstract] [Full Text] [Related]
18. Human immunodeficiency virus type 1-specific [2',5'-bis-O-(tert- butyldimethylsilyl)-beta-D-ribofuranosyl]-3'-spiro-5"-(4"-amino-1",2"- oxathiole-2",2"-dioxide)-purine analogues show a resistance spectrum that is different from that of the human immunodeficiency virus type 1-specific non-nucleoside analogues.
Balzarini J; Velazquez S; San-Felix A; Karlsson A; Perez-Perez MJ; Camarasa MJ; De Clercq E
Mol Pharmacol; 1993 Jan; 43(1):109-14. PubMed ID: 7678689
[TBL] [Abstract][Full Text] [Related]
19. Novel series of [ddN]-[TSAO-T] heterodimers as potential bi-functional inhibitors of HIV-1 RT. Studies in the linker and ddN region.
Velázquez S; Tuñón V; Jimeno ML; Pérez-Pérez MJ; San-Félix A; Chamorro C; Lobatón E; Esteban-Gamboa A; De Clercq E; Balzarini J; Camarasa MJ
Nucleosides Nucleotides; 1999; 18(4-5):1029-30. PubMed ID: 10432737
[TBL] [Abstract][Full Text] [Related]
20. Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.
Zhang Z; Walker M; Xu W; Shim JH; Girardet JL; Hamatake RK; Hong Z
Antimicrob Agents Chemother; 2006 Aug; 50(8):2772-81. PubMed ID: 16870771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
